| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,560,000 |
| Market
Cap: |
167.04(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.89 - $14.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.3 |
| Insider 3/6 Months : 21.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Solid Biosciences is engaged in curing Duchenne muscular dystrophy (Duchenne), a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are Co.'s gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Co.'s SGT-001 and SGT-003 vectors are derived from a naturally occurring, non-pathogenic virus called adeno-associated virus, which were selected for their ability to enter skeletal, diaphragm and cardiac muscle tissues.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
4,314,873 |
4,314,873 |
4,314,873 |
| Total Buy Value |
$0 |
$23,861,248 |
$23,861,248 |
$23,861,248 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
139 |
35,077 |
35,564 |
37,528 |
| Total Sell Value |
$1,111 |
$122,185 |
$124,549 |
$139,259 |
| Total People Sold |
1 |
7 |
7 |
8 |
| Total Sell Transactions |
1 |
8 |
9 |
12 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smith Ian F |
|
– • – |
2024-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,256 |
103,207 |
|
- |
|
| Ganot Ilan |
|
– • – |
2024-01-29 |
4 |
S |
$7.99 |
$1,111 |
I/I |
(139) |
8,416 |
|
-7% |
|
| Ganot Ilan |
|
– • – |
2024-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,883 |
94,807 |
|
- |
|
| Ganot Ilan |
|
– • – |
2024-01-27 |
4 |
OE |
$0.00 |
$0 |
I/I |
388 |
8,555 |
|
- |
|
| Bcls Ii Equity Opportunities, Lp |
|
– • • |
2024-01-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
904,160 |
|
11% |
|
| Ra Capital Nexus Fund, L.p. |
Director |
– • • |
2024-01-11 |
4 |
B |
$5.53 |
$5,000,005 |
I/I |
904,160 |
4,192,216 |
2.25 |
11% |
|
| Edelman Joseph |
Director |
– • • |
2024-01-11 |
4 |
B |
$5.53 |
$18,861,243 |
I/I |
3,410,713 |
6,833,539 |
2.25 |
11% |
|
| Koppel Adam |
|
– • • |
2024-01-11 |
4 |
A |
$5.53 |
$5,000,005 |
I/I |
904,160 |
4,034,582 |
|
- |
|
| Bcip Life Sciences Associates, Lp |
|
– • • |
2024-01-11 |
4 |
A |
$5.53 |
$5,000,005 |
I/I |
904,160 |
4,034,582 |
|
- |
|
| Tan Kevin |
CFO & Treasurer |
• – – |
2024-01-09 |
4 |
S |
$8.20 |
$32,267 |
D/D |
(3,935) |
9,308 |
|
-6% |
|
| Tan Kevin |
CFO & Treasurer |
• – – |
2024-01-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
13,243 |
|
- |
|
| Smith Ian F |
|
– • – |
2024-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,570 |
99,948 |
|
- |
|
| Ganot Ilan |
|
– • – |
2024-01-03 |
4 |
S |
$5.30 |
$6,052 |
I/I |
(1,142) |
8,167 |
|
-48% |
|
| Ganot Ilan |
|
– • – |
2024-01-03 |
4 |
OE |
$0.00 |
$0 |
I/I |
2,993 |
9,309 |
|
- |
|
| Herzich Paul |
Chief Technology Officer |
• – – |
2023-12-04 |
4 |
AS |
$2.77 |
$8,232 |
D/D |
(2,968) |
4,270 |
|
191% |
|
| Hanrahan Jessie |
Chief Regulatory Officer |
• – – |
2023-12-04 |
4 |
AS |
$2.78 |
$13,562 |
D/D |
(4,879) |
6,983 |
|
191% |
|
| Marlowe Jennifer |
CSO |
• – – |
2023-12-04 |
4 |
AS |
$2.77 |
$13,525 |
D/D |
(4,890) |
6,998 |
|
191% |
|
| Cumbo Alexander |
President and CEO |
• • – |
2023-12-04 |
4 |
AS |
$2.77 |
$32,516 |
D/D |
(11,757) |
17,439 |
|
191% |
|
| Howton David T |
Chief Operating Officer |
• – – |
2023-12-04 |
4 |
AS |
$2.78 |
$14,920 |
D/D |
(5,367) |
7,684 |
|
191% |
|
| Herzich Paul |
Chief Technology Officer |
• – – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,238 |
7,238 |
|
- |
|
| Hanrahan Jessie |
Chief Regulatory Officer |
• – – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,862 |
11,862 |
|
- |
|
| Marlowe Jennifer |
CSO |
• – – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,888 |
11,888 |
|
- |
|
| Cumbo Alexander |
President and CEO |
• • – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,612 |
29,196 |
|
- |
|
| Ganot Ilan |
|
– • – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,583 |
90,924 |
|
- |
|
| Howton David T |
Chief Operating Officer |
• – – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,051 |
13,051 |
|
- |
|
129 Records found
|
|
Page 1 of 6 |
|
|
0.23 (2.62%) 
